SGLT2 inhibitors for diabetes: Turning symptoms into therapy

The Lancet

Volumn 382, Issue 9896, 2013, Pages 917-918

  Diamant, Michaela ^a   Morsink, Linde M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BI 44847; CANAGLIFLOZIN; DAPAGLIFLOZIN; EGT 0001442; EGT 0001474; EMPAGLIFLOZIN; ERTUGLIFLOZIN; FAT; GLIMEPIRIDE; GLUCOSE; GSK 1614235; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; ISIS SGLT 2RX; LX 4211; METFORMIN; PHLORIZIN; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; TS 071; UNCLASSIFIED DRUG;

BODY COMPOSITION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; GENE MUTATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLUCOSURIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LEAN BODY WEIGHT; MALABSORPTION; MICTURITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSMOTIC DIURESIS; PANCREAS DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RENAL DIABETES; SIDE EFFECT; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION;

EID: 84884125716     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60902-2     Document Type: Note

References (13)

1. Barnett DM, Krall LP The history of diabetes. In: Kahn CR, Weir GC, King GL, Moses AC, Smith RJ, Jacobson AM, eds. Joslin's diabetes mellitus, 14th edition. Boston: Lippincott Williams & Wilkins, 2005: 1-17.
2. Bergman HC, Drury DR The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol 1938; 124: 279-84.
3. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-42.
4. Farber SJ, Berger EY, Earle DP Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-29.
5. Meyer C, Stumvoll M, Nadkarni V., Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-24.
6. Rahmoune H, Thompson PW, Ward J.M., Smith CD, Hong G, Brown J. Glucose transporters in the human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 2005; 54: 3427-34.
7. Santer R, Kinner M, Lassen C.L., et al Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14: 2873-82.
8. Cefalu WT, Leiter LA, Yoon K-H, et al Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; published online July 12. http://dx.doi.org/10.1016/S0140-6736(13)60683-2.
9. US Food and Drug Administration. FDA approves invokana to treat type 2 diabetes. March 29, 2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm345848.htm (accessed April 3, 2013).
10. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012; 379: 507.
11. European Medicines Agency. Forgixa. Dec 7, 2012. http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human-med-001546. jsp&mid=WC0b01ac058001d124 (accessed April 3, 2013).
12. Inzucchi SE, Bergenstal RM, Buse J.B., et al Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2012; 35: 1364-79.
13. US Food and Drug Administration. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. Jan 10, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM334551.pdf (accessed April 3, 2013).